CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $4.66M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 1.08: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
286.26MGBP390.83M · vs all stocks (USD)
Revenue (TTM)
3.41MGBP4.66M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.7710xvs all stocks
52-Week Change
-12.24%vs all stocks
Market Capitalization
286.26MGBP390.83M · vs all stocks (USD)
Enterprise Value
140.92MGBP192.39M · vs all stocks (USD)
Forward P/E
-4.04xvs Biotechnology peers
Price to Sales (TTM)
61.44xvs Biotechnology peers
Price to Book (MRQ)
1.23xvs Biotechnology peers
Enterprise to Revenue
41.31xvs Biotechnology peers
Enterprise to EBITDA
-1.99xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1797.79%vs Biotechnology peers
Return on Assets (TTM)
-10.82%vs Biotechnology peers
Return on Equity (TTM)
-30.85%vs Biotechnology peers
Revenue (TTM)
3.41MGBP4.66M · vs all stocks (USD)
Revenue per Share (TTM)
0.0190GBPUpdated Aug 22, 2026Quarterly Revenue Growth
-38.20%vs Biotechnology peers
Gross Profit (TTM)
-37.93MGBP-51.78M · vs all stocks (USD)
EBITDA (TTM)
-70.90MGBP-96.80M · vs all stocks (USD)
Net Income (TTM)
-80.35MGBP-109.70M · vs all stocks (USD)
Operating Cash Flow (TTM)
-62.33MGBP-85.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-65.89MGBP-89.96M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-6.40MUSDFY2025 · Dec 31, 2025Revenue
4.66MUSDFY2025 · Dec 31, 2025Operating Income
-98.53MUSDvs all stocks (USD)
Pre-tax Income
-110.93MUSDFY2025 · Dec 31, 2025Income Tax Expense
-842.00KUSDFY2025 · Dec 31, 2025Net Income
-110.08MUSDFY2025 · Dec 31, 2025EBIT
-65.15MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-102.36MUSDFY2025 · Dec 31, 2025Research & Development
45.74MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
20.65MUSDFY2025 · Dec 31, 2025Other Operating Expenses
1.03MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.05MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
45.78MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.4600USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.4600USDFY2025 · Dec 31, 2025Basic Shares Outstanding
240.79MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
240.79MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-110.08MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
345.00KUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-69.37MUSDFY2025 · Dec 31, 2025Free Cash Flow
-69.63MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
252.47MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-110.08MUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.22MUSDFY2025 · Dec 31, 2025Other Non-cash Items
32.73MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-236.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
0.00USDFY2025 · Dec 31, 2025Capital Expenditures
263.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Net Acquisitions
-888.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-84.20MUSDFY2025 · Dec 31, 2025Sale of Investments
148.06MUSDFY2025 · Dec 31, 2025Other Investing Activity
49.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
63.29MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-2.05MUSDFY2025 · Dec 31, 2025Other Financing Charges
-802.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.75MUSDFY2025 · Dec 31, 2025Shares Outstanding
241.68MSharesUpdated Aug 22, 2026Float Shares
156.80MSharesUpdated Aug 22, 2026% Held by Insiders
10.05%vs all stocks
% Held by Institutions
52.19%vs all stocks
Total Cash (MRQ)
211.40MGBP288.62M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.19GBPUpdated Aug 22, 2026Total Debt (MRQ)
148.82MGBP203.19M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6649xvs Biotechnology peers
Current Ratio (MRQ)
6.59xvs Biotechnology peers
Book Value per Share (MRQ)
0.9570GBPUpdated Aug 22, 2026Total Assets
534.71MUSDvs all stocks (USD)
Total Current Assets
305.02MUSDFY2025 · Dec 31, 2025Total Liabilities
229.03MUSDFY2025 · Dec 31, 2025Total Non-current Assets
229.69MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
182.72MUSDFY2025 · Dec 31, 2025Total Current Liabilities
46.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
252.47MUSDFY2025 · Dec 31, 2025Other Short-term Investments
24.83MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.76MUSDFY2025 · Dec 31, 2025Accounts Payable
3.07MUSDFY2025 · Dec 31, 2025Short-term Debt
8.50MUSDFY2025 · Dec 31, 2025Other Current Liabilities
13.42MUSDFY2025 · Dec 31, 2025Long-term Debt
11.09MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
170.42MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.86MUSDFY2025 · Dec 31, 2025Retained Earnings
-77.23MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
305.68MUSDvs all stocks (USD)
Treasury Stock
41.15MUSDFY2025 · Dec 31, 202552-Week Low
104.71GBXUpdated Aug 22, 202652-Week High
143.60GBXUpdated Aug 22, 202652-Week Change
-12.24%vs all stocks
Beta
0.7710xvs all stocks
50-Day MA
123.82GBXUpdated Aug 22, 2026200-Day MA
125.67GBXUpdated Aug 22, 2026Avg 10-Day Volume
500.55KSharesUpdated Aug 22, 2026Avg 30-Day Volume
585.85KSharesUpdated Aug 22, 2026Diluted EPS (TTM)
-0.3400GBPUpdated Aug 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.59Altman Z-Score: 1.08
Financial Health
Altman Z-Score 1.08: distress zoneCritical
Altman Z-Score: 1.08
Low earnings qualitySignificant
Earnings Quality Score: -0.58
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $4.66M, lower than 95% of all stocks globallySignificant
Revenue (USD): 4,657,507.944Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Upstream Bio, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Evolus Inc.
Tier 1ProductionApproval-Gated PipelineAttentionInterface
Crescent Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Abclon Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eupraxia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk